Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma

Inclusion Criteria: * Male or female patients at least 18 years or older (females less than one year post-menopausal must have a negative serum or urine pregnancy test recorded within 72 hours prior to the first dose of study medication, be non-lactating, and willing to use adequate and highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilization, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device, hormonal), sexual abstinence or vasectomised partner). * Known history of mild to moderate-severe reversible asthma for \> 6 months prior to the screening visit. * Demonstrate a FEV1 of \>40% to \<80% for predicted normal values (EGKS normal values, 1983) during the screening phase following appropriate withholding of asthma medications (if applicable). * No beta agonist use on day of screening. * No use of combination asthma therapy on day of screening. * Inhaled corticosteroids are allowed on day of screening. * Documented reversibility of \> 15% in FEV1 in the screening phase. * Demonstrate satisfactory technique in the use of the pressurized MDI. * Willing and able to enter information in the electronic diary and attend all study visits. * Willing and able to substitute study medication for their pre study prescribed asthma medication for the duration …